Organogenesis Holdings (ORGO) Operating Margin (2017 - 2026)
Organogenesis Holdings' (ORGO) quarterly Operating Margin came in at 185.05% in Q1 2026, down 15420.0% year-on-year from N/an in Q1 2025, and down 759.66% quarter-over-quarter from 28.05% in Q4 2025.
Organogenesis Holdings (ORGO) Operating Margin (2017 - 2026) Analysis & Trends
Organogenesis Holdings' Operating Margin history runs 10 years deep, the most recent figure standing at 185.05% for Q1 2026.
- On a quarterly basis, Operating Margin fell 15420.0% year-over-year to 185.05% in Q1 2026; TTM through Mar 2026 was 0.5%, a 577.0% increase from a year earlier, with the FY2025 full-year figure at 7.92%, up 819.0% from the prior year.
- Operating Margin retreated to 185.05% in Q1 2026 per ORGO's latest filing, from 28.05% in the prior quarter.
- Across five years, Operating Margin topped out at 28.05% in Q4 2025 and bottomed at 185.05% in Q1 2026.
- The 5-year median for Operating Margin is 1.52% (2022), against an average of 9.28%.
- Across the five-year window, Operating Margin jumped 1998 bps in 2025 and sank 15420 bps in 2026, its largest moves.
- Year by year, Operating Margin stood at 7.55% in 2022, then sank by 117 bps to 1.27% in 2023, then soared by 734 bps to 8.07% in 2024, then surged by 248 bps to 28.05% in 2025, then plunged by 760 bps to 185.05% in 2026.
- Per Business Quant, the three latest ORGO Operating Margin figures stand at 185.05% (Q1 2026), 28.05% (Q4 2025), and 13.74% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | Organogenesis Holdings | 310.55 Mn | 218.45 Mn | 11.46 Mn | -185.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -185.05% |
| Dec 31, 2025 | 28.05% |
| Sep 30, 2025 | 13.74% |
| Jun 30, 2025 | -12.45% |
| Mar 31, 2025 | -30.85% |
| Dec 31, 2024 | 8.07% |
| Sep 30, 2024 | 5.42% |
| Jun 30, 2024 | -10.67% |
| Mar 31, 2024 | -3.50% |
| Dec 31, 2023 | -1.27% |
| Sep 30, 2023 | 7.42% |
| Jun 30, 2023 | 8.31% |
| Mar 31, 2023 | -3.72% |
| Dec 31, 2022 | 7.55% |
| Sep 30, 2022 | 1.52% |
| Jun 30, 2022 | 9.83% |
| Mar 31, 2022 | -0.13% |
| Dec 31, 2021 | 15.45% |
| Sep 30, 2021 | 14.30% |
| Jun 30, 2021 | 19.15% |